KR101599384B1 - 임상적으로 잠복기 미생물을 사멸시키기 위한 ４­（피롤리딘­１­일）퀴놀린 화합물의 용도 - Google Patents

임상적으로 잠복기 미생물을 사멸시키기 위한 ４­（피롤리딘­１­일）퀴놀린 화합물의 용도 Download PDF

Info

Publication number
KR101599384B1
KR101599384B1 KR1020097026394A KR20097026394A KR101599384B1 KR 101599384 B1 KR101599384 B1 KR 101599384B1 KR 1020097026394 A KR1020097026394 A KR 1020097026394A KR 20097026394 A KR20097026394 A KR 20097026394A KR 101599384 B1 KR101599384 B1 KR 101599384B1
Authority
KR
South Korea
Prior art keywords
methyl
formula
compound
phenylpyrrolidin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097026394A
Other languages
English (en)
Korean (ko)
Other versions
KR20100021476A (ko
Inventor
만디 크리스틴 베스윅
수잔 메리 크람프
얀민 후
토마스 데이비드 팔린
하젤 조안 디케
앤쏘니 코테스
Original Assignee
헬퍼바이 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0709489A external-priority patent/GB0709489D0/en
Priority claimed from GB0807591A external-priority patent/GB0807591D0/en
Application filed by 헬퍼바이 테라퓨틱스 리미티드 filed Critical 헬퍼바이 테라퓨틱스 리미티드
Publication of KR20100021476A publication Critical patent/KR20100021476A/ko
Application granted granted Critical
Publication of KR101599384B1 publication Critical patent/KR101599384B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D345/00—Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020097026394A 2007-05-17 2008-05-16 임상적으로 잠복기 미생물을 사멸시키기 위한 ４­（피롤리딘­１­일）퀴놀린 화합물의 용도 Expired - Fee Related KR101599384B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0709489A GB0709489D0 (en) 2007-05-17 2007-05-17 New use
GB0709489.9 2007-05-17
GB0807591.3 2008-04-25
GB0807591A GB0807591D0 (en) 2008-04-25 2008-04-25 New use

Publications (2)

Publication Number Publication Date
KR20100021476A KR20100021476A (ko) 2010-02-24
KR101599384B1 true KR101599384B1 (ko) 2016-03-03

Family

ID=39672613

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097026394A Expired - Fee Related KR101599384B1 (ko) 2007-05-17 2008-05-16 임상적으로 잠복기 미생물을 사멸시키기 위한 ４­（피롤리딘­１­일）퀴놀린 화합물의 용도

Country Status (20)

Country Link
US (1) US8759348B2 (enExample)
EP (1) EP2182950B8 (enExample)
JP (1) JP5474768B2 (enExample)
KR (1) KR101599384B1 (enExample)
CN (1) CN101795688B (enExample)
AU (1) AU2008252636B2 (enExample)
BR (1) BRPI0811745B1 (enExample)
CA (1) CA2684692C (enExample)
DK (1) DK2182950T3 (enExample)
ES (1) ES2637999T3 (enExample)
HR (1) HRP20171553T1 (enExample)
HU (1) HUE034298T2 (enExample)
IL (1) IL201392A (enExample)
MX (1) MX2009012390A (enExample)
NZ (1) NZ580625A (enExample)
PL (1) PL2182950T3 (enExample)
PT (1) PT2182950T (enExample)
RU (1) RU2520766C2 (enExample)
SI (1) SI2182950T1 (enExample)
WO (1) WO2008142384A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010095522A (ja) * 2008-09-19 2010-04-30 Sumitomo Chemical Co Ltd 植物病原菌による植物病害を防除又は予防するための農業用組成物
SI2552440T1 (sl) 2010-03-30 2019-03-29 Helperby Therapeutics Limited Nove kombinacije in uporaba
EP2569302A1 (en) * 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
GB201013207D0 (en) 2010-08-05 2010-09-22 Helperby Therapeutics Ltd Novel combination
WO2012017215A1 (en) 2010-08-05 2012-02-09 Helperby Therapeutics Limited Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
JP6804096B2 (ja) 2015-04-11 2020-12-23 ヘルパービー セラピューティクス リミテッドＨｅｌｐｅｒｂｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 口腔用組成物
US10329257B2 (en) 2015-08-13 2019-06-25 The Broad Institute, Inc. Compositions and methods for treating tuberculosis
GB201518969D0 (en) 2015-10-27 2015-12-09 Helperby Therapeutics Ltd Triple combination
US11253511B2 (en) 2016-01-04 2022-02-22 The Johns Hopkins University Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)
KR102665309B1 (ko) * 2016-10-27 2024-05-10 주식회사 엘지생활건강 코디세핀을 포함하는 구강질환 예방 또는 치료용 조성물
GB201703898D0 (en) 2017-03-10 2017-04-26 Helperby Therapeautics Ltd Method
RU2664177C1 (ru) * 2017-08-07 2018-08-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) Способ лечения абсцедирующих фурункулов верхней и нижней зон лица
CN111163766A (zh) * 2017-08-17 2020-05-15 医肯纳肿瘤学公司 Ahr抑制剂和其用途
US10668046B2 (en) 2017-12-18 2020-06-02 Ansella Therapeutics, Inc. Compositions and methods for preventing and treating conditions
CN110897032B (zh) * 2019-11-19 2025-10-14 华南理工大学 一种发酵饲料蛋白及其制备方法与应用
RU2758056C2 (ru) * 2019-11-21 2021-10-26 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Препарат для лечения отитов бактериальной и грибковой этиологии у собак
CN111544599B (zh) * 2020-07-10 2020-12-01 有术肌肤管理(深圳)有限公司 一种用于治疗痤疮的化合物及其用于制备药物或化妆品的用途
KR102461715B1 (ko) * 2020-10-12 2022-11-02 대한민국 항균 및 항진균 활성을 나타내는 신균주 페니실리움 비세티 및 이의 용도
CN114831924A (zh) * 2021-03-17 2022-08-02 武汉恒信源药业有限公司 一种乌洛托品及其化合物的阴道局部给药制剂及用途
CN113528388A (zh) * 2021-07-19 2021-10-22 海南大学 珊瑚共生链霉菌、发酵生产放线菌素d的方法及应用
SMT202500447T1 (it) 2021-11-02 2026-01-12 Flare Therapeutics Inc Agonisti inversi di pparg e loro usi
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CN117323339A (zh) * 2023-09-05 2024-01-02 中国科学院广州生物医药与健康研究院 偶氮丝氨酸在制备抗分枝杆菌的药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
EP2048142A3 (en) * 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
AU2002338896B2 (en) * 2001-05-21 2006-04-27 F.Hoffman-La Roche Ag Quinoline derivatives as ligands for the neuropeptide Y receptor
US6787558B2 (en) * 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
EP1451156A4 (en) * 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
PL372295A1 (en) * 2002-02-04 2005-07-11 F.Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
CA2489560A1 (en) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
WO2004016321A2 (en) * 2002-08-19 2004-02-26 Avi Elbaz Proprioceptive/kinesthetic apparatus and method
JP4602903B2 (ja) * 2002-10-10 2010-12-22 モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー 抗菌活性を有する新規化合物
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
DE102004041163A1 (de) * 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
GB0522715D0 (en) * 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use

Also Published As

Publication number Publication date
AU2008252636A1 (en) 2008-11-27
SI2182950T1 (en) 2018-01-31
HRP20171553T1 (hr) 2017-12-15
KR20100021476A (ko) 2010-02-24
IL201392A (en) 2016-03-31
NZ580625A (en) 2011-12-22
IL201392A0 (en) 2010-05-31
EP2182950B8 (en) 2017-08-23
HUE034298T2 (en) 2018-02-28
BRPI0811745B1 (pt) 2019-06-04
DK2182950T3 (da) 2017-11-06
CN101795688A (zh) 2010-08-04
WO2008142384A1 (en) 2008-11-27
US20100305065A1 (en) 2010-12-02
BRPI0811745A2 (pt) 2014-11-11
EP2182950A1 (en) 2010-05-12
PL2182950T3 (pl) 2018-01-31
JP2010527346A (ja) 2010-08-12
RU2520766C2 (ru) 2014-06-27
AU2008252636B2 (en) 2013-10-31
PT2182950T (pt) 2017-09-11
RU2009146828A (ru) 2011-06-27
CN101795688B (zh) 2015-05-20
CA2684692A1 (en) 2008-11-27
JP5474768B2 (ja) 2014-04-16
CA2684692C (en) 2016-07-05
US8759348B2 (en) 2014-06-24
ES2637999T3 (es) 2017-10-18
MX2009012390A (es) 2010-06-23
EP2182950B1 (en) 2017-07-19

Similar Documents

Publication Publication Date Title
RU2520766C2 (ru) Применение соединений 4-(пирролидин-1-ил)хинолина для уничтожения клинически латентных микроорганизмов
US10493071B2 (en) Use of pyrroloquinoline compounds to kill clinically latent microorganisms
JP5559541B2 (ja) 局所製剤
WO2008117079A1 (en) Antimicrobial compounds based upon 4-aminoquinoline
MX2012011236A (es) Combinacion y usos novedosos.
HK1140146B (en) Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
HK1140146A (en) Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
MX2008006079A (en) Use of pyrroloquinoline compounds to kill clinically latent microorganisms

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190222

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200226

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200226

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000